Deutsche Bank AG Raises Stock Position in LifeMD, Inc. (NASDAQ:LFMD)

Deutsche Bank AG boosted its stake in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 7,853.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,333 shares of the company's stock after purchasing an additional 44,763 shares during the quarter. Deutsche Bank AG owned about 0.10% of LifeMD worth $224,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of LFMD. Marshall Wace LLP lifted its stake in LifeMD by 522.9% in the 4th quarter. Marshall Wace LLP now owns 371,473 shares of the company's stock worth $1,839,000 after purchasing an additional 311,841 shares in the last quarter. Royce & Associates LP raised its position in shares of LifeMD by 23.9% during the 4th quarter. Royce & Associates LP now owns 1,115,991 shares of the company's stock valued at $5,524,000 after buying an additional 214,950 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of LifeMD by 21.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company's stock valued at $4,610,000 after buying an additional 165,378 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of LifeMD by 45.2% during the 4th quarter. Renaissance Technologies LLC now owns 510,000 shares of the company's stock valued at $2,524,000 after buying an additional 158,796 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in shares of LifeMD by 825.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 158,423 shares of the company's stock valued at $784,000 after buying an additional 141,307 shares in the last quarter. Hedge funds and other institutional investors own 35.52% of the company's stock.

LifeMD Stock Down 1.7%

Shares of NASDAQ LFMD traded down $0.21 during midday trading on Thursday, reaching $12.08. 1,920,976 shares of the company's stock traded hands, compared to its average volume of 1,003,357. The stock's 50 day simple moving average is $7.97 and its 200-day simple moving average is $6.46. LifeMD, Inc. has a one year low of $3.99 and a one year high of $13.25. The company has a market cap of $549.01 million, a price-to-earnings ratio of -18.88 and a beta of 2.42.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million during the quarter, compared to analyst estimates of $62.47 million. Equities analysts predict that LifeMD, Inc. will post -0.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other LifeMD news, CMO Jessica Friedeman sold 30,000 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $5.66, for a total value of $169,800.00. Following the completion of the transaction, the chief marketing officer now owns 170,000 shares of the company's stock, valued at approximately $962,200. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Justin Schreiber sold 25,000 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $12.47, for a total transaction of $311,750.00. Following the completion of the transaction, the chief executive officer now directly owns 2,525,721 shares of the company's stock, valued at approximately $31,495,740.87. This represents a 0.98% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 126,995 shares of company stock valued at $1,036,172. Insiders own 18.40% of the company's stock.

Analyst Upgrades and Downgrades

LFMD has been the topic of several recent research reports. Cantor Fitzgerald restated an "overweight" rating and set a $15.00 target price on shares of LifeMD in a research report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of LifeMD in a research note on Wednesday, April 30th. Finally, B. Riley upgraded shares of LifeMD to a "strong-buy" rating in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, LifeMD currently has a consensus rating of "Buy" and a consensus price target of $11.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.